Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)

Detalles Bibliográficos
Autores principales: Patel, Sapna, Milhem, Mohammed, Hallmeyer, Sigrun, Daniels, Gregory, Cranmer, Lee, Taback, Bret, Flaherty, Lawrence, Aung, Sandra, Lowder, James, Sharfman, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288743/
http://dx.doi.org/10.1186/2051-1426-2-S3-P78
Descripción
Sumario:

Ejemplares similares